URGN Q4 2025 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38M+54.0% YoY

Gross Profit

$35M91.3% margin

Operating Income

-$19M-50.5% margin

Net Income

-$26M-69.7% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

+37.7%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$38M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$200M

Total Liabilities

$306M

Stockholders' Equity

-$105M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$25M	+54.0%
Gross Profit	$35M	$22M	+56.4%
Operating Income	-$19M	-$28M	+30.9%
Net Income	-$26M	-$38M	+29.7%

Revenue Segments

Jelmyto

$24M100%